Positive results for MS drug

Published: 2-Mar-2001


Elan and Biogen have announced positive results from two Phase II clinical studies on natalizumab (Antegren) in treating multiple sclerosis and Crohn's disease. The companies hope to start Phase III trials on the humanised monoclonal antibody this year.

You may also like